Mexichem Buys German Chemical Producer for $292 Million

Mexican petrochemical producer Mexichem said it had signed a "definite agreement" with US-based private equity investor Strategic Value Partners to acquire German PVC producer Vestolit for $292 million in cash and assumed liabilities.

Following regulatory approval, the asset transfer is expected to be finalized in the fourth quarter of this year, Mexichem said.

The German company is Europe's sole manufacturer of high-impact PVC specialties for applications such as weather-resistant windows.

"The acquisition of Vestolit is in keeping with our strategy of becoming a global, vertically integrated chemical company with a focus on high-end, specialized products," Mexichem CEO Antonio Carrillo said in a statement, adding that the PVC producer's current management will be retained.

Vestolit CEO Michael Träger said the link-up with its new Mexican owner "is a major step that will strengthen the company's back-integrated production site at Marl."  

SVP acquired the PVC producer, which has annual sales of €500 million, EBITDA of 40 million and capacity to produce 400,000 t/y of PVC, in 2006 from a consortium led by private investor Candover Partners.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.